Alsevalimab is under development as a experimental therapeutic antibody targeting B7-H4. This therapy has shown initial efficacy in several cancer forms by reducing B7-H4 protein's role in tumor spread and patient https://fpa150126033.blog-gold.com/60287732/alsevalimab-an-emerging-b7h4-immune-agent-in-clinical-trials